title: Effects of angiogenesis inhibition by spironolactone on isolated vas deferens contractility in an experimental varicocele model in rats.
abstract: OBJECTIVE
  To investigate the effect of spironolactone, as an angiogenesis inhibitor, on the isometric contractile responses in isolated vas deferens strips from left varicocele-induced rats.
  
  
  METHODS
  Twenty-four adult (12-14 months) male Wistar albino rats were randomly assigned to 4 groups (n = 6 in each): (1) Control group, (2) sham-operated group, (3) experimental left varicocele group, and (4) Spironolactone (20 mg/kg/d)-treated experimental left varicocele group. Histopathologic and immunohistochemical (CD31 staining) findings in the rat testis and functional findings in the rat isolated vas deferens were investigated.
  
  
  RESULTS
  Angiogenesis increased in the varicocele group and the spironolactone inhibited angiogenesis in the spironolactone-treated group. Spironolactone seemed to change phenylephrine and serotonin responses in the left vas deferens.
  
  
  CONCLUSIONS
  It is possible that by inhibiting angiogenesis, spironolactone treatment negatively impairs testicular morphology and functional (vas deferens) pathways. Varicocele formation seems to elicit an increase to 5-HT sensitivity in rat vas deferens, and this process is prevented by spironolactone pretreatment.
authors.affiliation: Department of Urology, Baskent University School of Medicine, Ankara, Turkey. vensyou@mynet.com
authors.forename: Mustafa Gökhan
authors.initials: MG
authors.lastname: Köse
authors.forename: Ş Remzi
authors.initials: ŞR
authors.lastname: Erdem
authors.forename: Çetin Levent
authors.initials: ÇL
authors.lastname: Peșkircioğlu
authors.forename: Berrin
authors.initials: B
authors.lastname: Çaylak
mesh_terms: D058646:Adrenergic alpha-1 Receptor Agonists / Q000494:pharmacology; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000494:pharmacology; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D055806:Microvessels; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010656:Phenylephrine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013091:Spermatogenesis / Q000187:drug effects; D013148:Spironolactone / Q000494:pharmacology*; D018709:Statistics, Nonparametric; D013737:Testis / Q000098:blood supply / Q000503:physiopathology; D014646:Varicocele / Q000503:physiopathology*; D014649:Vas Deferens / Q000098:blood supply / Q000187:drug effects* / Q000502:physiology
chemical_list: D058646:Adrenergic alpha-1 Receptor Agonists; D058668:Adrenergic alpha-1 Receptor Antagonists; D020533:Angiogenesis Inhibitors; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D010656:Phenylephrine; D013148:Spironolactone; D012701:Serotonin; D007650:Ketanserin; D011224:Prazosin